Durability as the New Standard in Cartilage Repair: Why Long-Term Results Are Reshaping Global Orthopedics

Austin, Texas, October 22nd, 2026, FinanceWire

• Orthopedic care is increasingly focused not only on relieving symptoms, but on delivering durable outcomes that can stand up over time.
• That shift is creating greater interest in regenerative approaches designed to restore damaged tissue rather than simply address the immediate effects of injury.
• Regentis Biomaterials is advancing this approach with GelrinC, a degradable hydrogel implant designed to support the regeneration of durable cartilage in the knee.

Orthopedic medicine has long focused on relieving pain and restoring mobility. Increasingly, though, the question is: How well will the result hold up over time?

One company pursuing this approach is Regentis Biomaterials Ltd. (NYSE American: RGNT), a regenerative medicine company developing tissue repair solutions with an initial focus on orthopedic applications. Its technology is built around the…

Read More>>

This content was disseminated on behalf of Regentis Biomaterials Ltd. (NYSE American: RGNT) as part of a paid marketing engagement with IBN.Ai

RGNT: IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN

NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer

The latest news and updates relating to RGNT are available in the company’s newsroom at https://ibn.fm/RGNT

Corporate Communications

IBN

Austin, Texas

www.IBN.ai

512.354.7000 Office

Editor@IBN.ai